U.S. Water Utilities Stock News

In January 2026, Viking Therapeutics reported published Phase 2 VENTURE trial data for its dual GLP-1/GIP agonist VK2735, showing statistically significant weight loss in people with obesity and a generally mild to moderate side-effect profile. The update also confirmed full enrollment of the large VANQUISH-1 Phase 3 obesity trial, ongoing VANQUISH-2 in type 2 diabetes, and a separate maintenance dosing study that could shape how VK2735 is used long term if approved. We’ll now examine how...

Earlier in January 2026, Guggenheim reaffirmed its positive view on Structure Therapeutics, pointing to increased confidence in its oral obesity drug aleniglipron and progress on the early-stage candidate ACCG-2671. Guggenheim also highlighted Structure Therapeutics’ licensing deal with Genentech, which includes a US$100,000,000 upfront payment and potential royalties, underscoring external validation of its pipeline. Next, we’ll examine how Guggenheim’s confidence in aleniglipron’s...

Short term move in context Carter's (CRI) has pulled back around 5.6% over the past day, even though the stock has shown a gain over the past month and the past 3 months. This has prompted some investors to reassess the recent move. See our latest analysis for Carter's. At a share price of $35.66, Carter's recent 5.6% one day pullback comes after a 30 day share price return of 12.46% and a year to date share price return of 7.41%. The 1 year total shareholder return of 31.08% and 5 year total...

Nextpower (NasdaqGS:NXT) has formed a joint venture with Abunayyan Holding to create Nextpower Arabia. The partnership includes a new large scale solar tracker manufacturing facility in Saudi Arabia to serve the Middle East and North Africa. The move expands Nextpower's presence into MENA, with a focus on localized production of solar tracking technology. For you as an investor, this places Nextpower directly in one of the most active regions for large utility scale solar projects. The...

Wondering whether United Parks & Resorts at around US$37.49 is a bargain or a value trap right now? This article walks through what the current price might be telling you about the stock. The share price is up 5.3% over the last month and 3.5% year to date, but that sits against a 27.6% decline over the last year and a 40.2% decline over three years, which may have shifted how investors see both risk and potential reward. Recent coverage around United Parks & Resorts has highlighted the...

President Trump has directed Federal National Mortgage Association (OTCPK:FNMA) to purchase up to US$200b in mortgage backed securities as part of a wider housing push. The administration is also pursuing steps to lower mortgage rates, restrict large institutional buyers of single family homes, and allow 401(k) funds to be used for down payments. These actions and proposals mark a significant shift in U.S. housing policy with direct implications for Fannie Mae and the broader mortgage...

National Bankshares (NKSH) just wrapped up FY 2025 with fourth quarter total revenue of US$15.9 million and basic EPS of US$0.92, alongside net income of US$5.9 million. Trailing twelve month figures show revenue of US$55.6 million and EPS of US$2.49. Over the last few quarters, revenue has gone from US$12.3 million in Q4 2024 to US$15.9 million in Q4 2025, with basic EPS shifting from US$0.48 to US$0.92 across the same period. Trailing EPS moved from US$1.24 to US$2.49 as net profit margin...

Investar Holding (ISTR) has wrapped up FY 2025 with fourth quarter revenue of US$23.5 million and EPS of US$0.55, set against trailing twelve month revenue of US$93.6 million and EPS of US$2.22 that point to a solidly profitable year. The company has seen revenue move from US$86.3 million and EPS of US$2.06 on a trailing basis at the end of Q4 2024 to US$93.6 million and EPS of US$2.22 by Q4 2025, with net profit margin over the last year at 24.5% compared to 23.5% previously. With earnings...

iQIYI (IQ) is back on traders’ radar after the immediate resignation of long-time CFO Jun Wang, the appointment of interim finance head Ying Zeng, and new headlines on content performance and international viewership. See our latest analysis for iQIYI. The CFO change and strong content headlines have arrived after a mixed run for shareholders, with a 7 day share price return of 4.9% and a 1 month share price return of 7.1%, but a 1 year total shareholder return decline of 8.7% and a 5 year...

Why Glacier Bancorp Stock Is On Investors’ Radar Today Glacier Bancorp (GBCI) has drawn fresh attention after recent share moves, with the stock showing mixed short term returns and a monthly gain along with a past 3 months increase and a 1 year decline. See our latest analysis for Glacier Bancorp. Glacier Bancorp’s recent pullback, with a 1 day share price return of 3.75% decline to $48.0, sits against a 30 day share price return of 4.83% and a 90 day share price return of 9.46%. Its 1 year...

Western Midstream Partners, LP recently declared a fourth-quarter 2025 cash distribution of US$0.910 per unit, payable on February 13, 2026, while simultaneously overhauling key Delaware Basin natural-gas gathering and processing contracts with Occidental Petroleum and adding a new fixed-fee agreement with ConocoPhillips. By shifting from cost-of-service to fixed-fee contracts, modestly reducing Occidental’s ownership stake, and lowering related-party revenue concentration, Western Midstream...

Bar Harbor Bankshares (BHB) just closed out FY 2025 with fourth quarter total revenue of US$48.2 million and basic EPS of US$0.70, supported by net income of US$11.8 million, while trailing twelve month figures show revenue of US$163.4 million and EPS of US$2.32. Over recent periods, quarterly revenue has moved from US$38.4 million in Q3 2024 to US$37.4 million in Q4 2024, then to US$37.3 million in Q1 2025 and US$44.0 million in Q3 2025 before reaching US$48.2 million in Q4 2025, as EPS...

Crinetics Pharmaceuticals has begun dosing pediatric patients in its Phase 2/3 BALANCE-CAH trial of atumelnant for classic congenital adrenal hyperplasia. Atumelnant is described as a first in class oral ACTH receptor antagonist and is currently the only small molecule in late stage development targeting this mechanism. The program received FDA Orphan Drug Designation for classic congenital adrenal hyperplasia, highlighting the focus on a rare pediatric condition with significant unmet...

Benchmark Electronics, Inc. previously announced it would release its fourth quarter and fiscal 2025 results on February 3, 2026, followed by a same-day conference call and webcast for investors. This update comes as the company contends with end-market headwinds, declining sales, subdued earnings growth, and a constrained free cash flow profile. We’ll now examine how these end-market challenges and thin free cash flow margins shape Benchmark Electronics’ broader investment narrative. We've...

BayCom (BCML) has wrapped up FY 2025 with fourth quarter total revenue of US$25.6 million and basic EPS of US$0.63, while trailing twelve month revenue came in at US$96.5 million with EPS of US$2.18. The company has seen revenue move from US$96.3 million and EPS of US$2.10 on a trailing basis at FY 2024 to the latest trailing totals of US$96.5 million and EPS of US$2.18. This sets the backdrop for investors to weigh consistent profitability against how margins might evolve from here. See our...

Heritage Commerce (HTBK) has just wrapped up FY 2025 with fourth quarter revenue of US$53.0 million and basic EPS of US$0.25, alongside trailing twelve month revenue of US$195.6 million and EPS of US$0.78 that reflect the latest run rate. The company has seen revenue move from US$170.3 million to US$195.6 million on a trailing basis, while EPS shifted from US$0.66 to US$0.78. This sets up a picture in which firmer earnings and slightly higher net profit margins are central to how investors...

South Atlantic Bancshares (SABK) has just wrapped up FY 2025 with fourth quarter total revenue of US$15.9 million and basic EPS of US$0.64, supported by net income of US$4.8 million. Over the past year, the company has seen total revenue move from US$13.4 million in Q4 2024 to US$15.9 million in Q4 2025, while trailing twelve month EPS stepped up from US$1.33 to US$2.15, setting the backdrop for reported earnings growth of 60.8% and a higher net profit margin of 26.9% versus 20.6% a year...

Webster Financial (WBS) has wrapped up FY 2025 with fourth quarter total revenue of US$704.2 million and basic EPS of US$1.62, capping a trailing twelve months in which revenue reached US$2.7 billion and EPS came in at US$5.98 alongside 32.5% year over year earnings growth. The company has seen quarterly revenue move from US$595.9 million in Q4 2024 to US$704.2 million in Q4 2025, while basic EPS stepped up from US$1.01 to US$1.62 over the same period. This sets the backdrop for investors to...

ACNB (ACNB) has wrapped up FY 2025 with fourth quarter revenue of US$36.6 million and EPS of US$1.04, supported by net income of US$10.8 million. Over the last few quarters, revenue has moved from US$26.6 million in Q4 2024 to US$41.3 million in Q3 2025 before landing at US$36.6 million in Q4 2025, while quarterly EPS has ranged from US$0.77 in Q4 2024 to US$1.43 in Q3 2025 and US$1.04 most recently, setting up a results season in which investors are weighing earnings power against the...

1st Source (SRCE) has just wrapped up FY 2025 with fourth quarter revenue of US$110.1 million and EPS of US$1.69, capping a trailing twelve month run of US$421.2 million in revenue and EPS of US$6.46. Over the past year, revenue has moved from US$374.7 million and EPS of US$5.36 on a trailing basis to US$421.2 million and EPS of US$6.46. Full year net income reached US$158.3 million. With margins now running at 37.6%, the latest numbers describe a bank that is monetizing its franchise...

National HealthCare (NHC) is back on investor radar after reporting 22.67% revenue growth, maintaining a "GREAT" financial health score and announcing a quarterly dividend of $0.64 per share. See our latest analysis for National HealthCare. That stronger backdrop has coincided with a 90 day share price return of 16.7% and a 1 year total shareholder return of 52.59%, suggesting momentum has been building around National HealthCare’s financial updates and dividend profile, even after a modest 1...

APA (APA) has put several moving pieces on the table ahead of its upcoming earnings call, including fourth quarter production curtailments, higher transaction costs and fresh analyst caution following a recent downgrade. See our latest analysis for APA. Those fourth quarter curtailments, higher transaction costs and the recent analyst downgrade come after a period where the share price has been edging higher. A 30 day share price return of 5.91% and a 90 day share price return of 8.27% have...

Kinder Morgan (KMI) just capped FY 2025 with Q4 revenue of US$4.5 billion and basic EPS of US$0.45, alongside net income of US$996 million, setting a clear marker for its latest reporting stretch. The company has seen quarterly revenue move from US$3.99 billion and EPS of US$0.30 in Q4 2024 to US$4.5 billion and EPS of US$0.45 in Q4 2025, with trailing twelve month EPS at US$1.37 and net income at US$3.1 billion providing a fuller earnings picture. With net profit margins highlighted as...

FS Bancorp (FSBW) has wrapped up FY 2025 with fourth quarter revenue of US$36.4 million and basic EPS of US$1.14, alongside trailing twelve month revenue of US$143.1 million and EPS of US$4.35 that reflect the broader earnings picture. Over the past year, the company has seen revenue move from US$139.2 million on a trailing basis in FY 2024 to US$143.1 million in FY 2025, while EPS shifted from US$4.48 to US$4.35, setting a mixed backdrop for the latest numbers. With a net profit margin of...